Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapies

Sunitinib in RCC—expanded access equals expanded benefit?

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. In an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer, R. J. et al. Sunitinib in patients with metastatic renal-cell carcinoma. JAMA 295, 2516–2524 (2006).

    Article  CAS  Google Scholar 

  2. Motzer, R. J. et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  3. Gore, M. E. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757–763 (2009).

    Article  CAS  Google Scholar 

  4. Eisen, T. et al. Sorafenib for older patients with renal-cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100, 1454–1463 (2008).

    Article  CAS  Google Scholar 

  5. Motzer, R. J. et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal-cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).

    Article  CAS  Google Scholar 

  6. Knox, J. J. et al. The Advanced Renal-Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy [abstract 5011]. J. Clin. Oncol. 25, 18S (2007).

    Google Scholar 

  7. Atkins, M. B. et al. Treatment selection for patients with metastatic renal-cell carcinoma. Cancer 115 (Suppl.), 2327–2333 (2009).

    Article  CAS  Google Scholar 

  8. Courtney, K. D. & Choueiri, T. K. Optimizing recent advances in metastatic renal-cell carcinoma. Curr. Oncol. Rep. 11, 218–226 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

    Toni K. Choueiri

  2. Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Michael B. Atkins

Authors
  1. Toni K. Choueiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Atkins.

Ethics declarations

Competing interests

T. K. Choueiri declares that he is a consultant for Bayer-Onyx, GlaxoSmithKline, Novartis and Pfizer. M. B. Atkins declares that he is a consultant for Aveo, Bayer-Onyx, Genentech, Novartis and Pfizer. M. B. Atkins is also on the speakers' bureau for Aero and has received grant/research funding from Bayer-Onyx, Genentech, Novartis and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choueiri, T., Atkins, M. Sunitinib in RCC—expanded access equals expanded benefit?. Nat Rev Clin Oncol 6, 679–680 (2009). https://doi.org/10.1038/nrclinonc.2009.170

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.170

  • Springer Nature Limited

This article is cited by

Search

Navigation